Dr. Jeremy M. Levin is Chairman and CEO of Ovid Therapeutics Inc (NASDAQ:OVID), a company whose mission is to bring treatment to patients with rare neurological conditions. Dr. Levin is concurrently the chairman of the Biotechnology Innovation Organization (BIO). Prior to founding Ovid, Dr. Levin was president and CEO of Teva Pharmaceutical Industries Ltd., (TLV: TEVA) Before Teva, Dr. Levin was member of the executive committee Bristol-Myers Squibb Company (NYSE: BMY). In that capacity he was the architect of and implemented the String of Pearls Strategy, which transformed Bristol. Dr. Levin joined BMY from Novartis (SWX: NOVN) where he was global head of strategic alliances. He has served on the board of directors of various public and private biopharmaceutical companies and is currently on the board of directors of Lundbeck (OMX: LUN).Dr. Levin was voted as one of the twenty-five most influential biotechnology leaders by Fierce Biotech and one of the top three biotechnology CEOs in 2020 by The Healthcare Technology Report. He is the recipient of the Albert Einstein Award for Leadership in Life Sciences and the B’nai B’rith Award for Distinguished Achievement. He has practiced medicine at university hospitals in England, South Africa, and Switzerland. Dr. Levin earned his bachelor’s degree in zoology and a master’s degree and doctorate in chromatin structure, at the University of Oxford, and thereafter his medical and surgical degrees from the University of Cambridge where he won the Kermode Prize for his work on Captopril
A collection of diverse viewpoints from over 45 thought leaders in the biotechnology industry and their efforts going forward during the COVID-19 pandemic.Biotechnology in the Time of COVID-19 is the opening chapter of a story of how the biotechnology industry rose to battle the COVID-19 virus—told by the leaders of that industry in their own words.The industry has built over more than forty years, an ecosystem of scientists, entrepreneurs, doctors, investors, venture capitalists, analysts, media, and bankers, all committed to advancing global health. In two months, leaders and companies from this ecosystem pivoted from the work they were carrying on pre-COVID-19 to face the virus. Forty-seven contributors offer historical, personal, and investor perspectives, views from inside the biotech companies, broad lessons, leadership, and a look to the future.COVID-19 was a crisis anticipated by many, but one for which we were inadequately prepared. That has led to an unnecessary catastrophe. Now is the time to shine a light on those who bring hope that we will push back the virus with science and medicine. This book is a collection of the voices from the front of that fight. All share the commitment to fight and the conviction that science and medicine will prevail.The editor royalties and a portion of publisher revenues will be donated to two nonprofits focused on rare disease research: Global Genes (globalgenes.org) and The Institute for Life Changing Medicines (lifechangingmedicines.org).
